Interleukin-15, human recombinant
Also known as: AMG 282, IL-15, Interleukin-15, N-803 (related superagonist), recombinant human interleukin‑15, rhIL-15
Source Interleukin-15, human recombinant at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Recombinant human Interleukin‑15 (rhIL‑15) is a biologic cytokine investigated for its ability to boost anti‑tumor and antiviral immunity by expanding NK and memory CD8⁺ T cells.
Mechanism of Action
Binds the IL-15 receptor complex (IL-15Rα/β/γ) to stimulate proliferation and activation of NK cells and CD8⁺ T lymphocytes, enhancing innate and adaptive immune responses.
Routes of Administration
Goals & Uses
- NK cell expansionImmunologyHigh
- Combination with checkpoint inhibitorsOncologyModerate
- CD8+ memory T cell homeostasisImmunologyHigh
- Enhance anti‑tumor immunityOncologyModerate
- HIV immunotherapy / viral reservoir reductionInfectious DiseaseLow
- Cancer immunotherapyOncologyModerate
- Boost antiviral responseInfectious DiseaseLow
Contraindications
- Severe cytokine release syndrome riskHematologicHigh
- Severe hepatic or renal impairmentOrgan ImpairmentModerate
- Organ transplant recipients on immunosuppressionTransplantHigh
- Active systemic infectionInfectiousHigh
- Active autoimmune diseaseAutoimmunityModerate
Adverse Effects
- Cytokine release syndromeImmunologicUncommonSystemic inflammatory response from immune activation
- Injection site reactionsLocalCommon
- ThrombocytopeniaHematologicCommonLow platelet count
- Cytokine release syndrome (CRS)ImmunologicalCommon
- HypotensionCardiovascularUncommonLow blood pressure
- Liver enzyme elevation (transaminitis)HepaticUncommon
- FatigueGeneralCommonLow energy or tiredness
- FeverSystemicCommonElevated body temperature
Drug Interactions
- Anti-PD-1/PD-L1 agents (e.g., pembrolizumab, nivolumab)Moderate
- Other pro-inflammatory cytokines (e.g., IL-2, IL-21)Moderate
- Immunosuppressive agents (e.g., cyclosporine, tacrolimus)High
- CyclosporineModerate
- CorticosteroidsModerate
Population Constraints
- Pediatric patientsAgeRelative
- Elderly patients (>75 years)AgeRelative
- Pregnant or lactating womenReproductiveRelative
- Patients with prior severe CRS or immunological toxicityMedical HistoryRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionInvestigationalClinical trial authorization in multiple member states.
- United StatesInvestigationalIND holder; ongoing Phase I/II trials.
- United KingdomInvestigationalNo MHRA approval; investigated in clinical trials within academic frameworks.
Not approved for any indication; currently in Phase I/II clinical trials for solid tumors, hematologic malignancies, and viral infections.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Interleukin-15, human recombinant?
Recombinant human Interleukin‑15 (rhIL‑15) is a biologic cytokine investigated for its ability to boost anti‑tumor and antiviral immunity by expanding NK and memory CD8⁺ T cells.
What is Interleukin-15, human recombinant used for?
Interleukin-15, human recombinant is educationally associated with: NK cell expansion, Combination with checkpoint inhibitors, CD8+ memory T cell homeostasis, Enhance anti‑tumor immunity, HIV immunotherapy / viral reservoir reduction, Cancer immunotherapy, Boost antiviral response. Educational only — not medical advice.
How is Interleukin-15, human recombinant administered?
Recorded routes of administration: Continuous Intravenous Infusion, Intravenous, Subcutaneous.
What are the potential side effects of Interleukin-15, human recombinant?
Reported adverse effects include: Cytokine release syndrome, Injection site reactions, Thrombocytopenia, Cytokine release syndrome (CRS), Hypotension, Liver enzyme elevation (transaminitis), Fatigue, Fever. This list is not exhaustive — consult a qualified clinician.
Who should avoid Interleukin-15, human recombinant?
Recorded contraindications: Severe cytokine release syndrome risk, Severe hepatic or renal impairment, Organ transplant recipients on immunosuppression, Active systemic infection, Active autoimmune disease. Consult a qualified clinician before use.